StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a report issued on Wednesday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Down 13.4 %

NASDAQ:OPGN opened at $0.94 on Wednesday. The firm’s 50-day moving average price is $1.05 and its 200-day moving average price is $1.68. OpGen has a 1-year low of $0.53 and a 1-year high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.